Results

#ASH18: Legend Biotech — allied with J&J now — continues to wow the crowd with their BCMA CAR-T update. What will bluebird say?

Back in the summer of 2017, an unknown Chinese biotech called Legend jumped into ASCO and disrupted the rep bluebird had carefully erected for itself as the breakaway leader among companies developing a BCMA-targeting CAR-T for multiple myeloma, offering up regular looks at one of the industry’s top development programs.

Legend offered startling proof-of-concept data to suggest that they could leapfrog the pack and land among the top companies pioneering the field. Soon after J&J followed up with a rich $350 million cash upfront to partner with Legend, offering their endorsement that the biotech was no fly-by-night pretender to the throne.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->